These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 18311895)

  • 21. Recent progress in ocular drug delivery for posterior segment disease: emphasis on transscleral iontophoresis.
    Myles ME; Neumann DM; Hill JM
    Adv Drug Deliv Rev; 2005 Dec; 57(14):2063-79. PubMed ID: 16310884
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Suppression of choroidal neovascularization by vaccination with epitope peptide derived from human VEGF receptor 2 in an animal model.
    Takahashi H; Ishizaki H; Tahara H; Tamaki Y; Yanagi Y
    Invest Ophthalmol Vis Sci; 2008 May; 49(5):2143-7. PubMed ID: 18436847
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prodrug of epigallocatechin-3-gallate alleviates choroidal neovascularization via down-regulating HIF-1α/VEGF/VEGFR2 pathway and M1 type macrophage/microglia polarization.
    Xu J; Tu Y; Wang Y; Xu X; Sun X; Xie L; Zhao Q; Guo Y; Gu Y; Du J; Du S; Zhu M; Song E
    Biomed Pharmacother; 2020 Jan; 121():109606. PubMed ID: 31743875
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Strategies for inhibiting vascular endothelial growth factor.
    Kaiser PK
    Retina; 2009 Jun; 29(6 Suppl):S15-7. PubMed ID: 19553789
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Approaches toward combining photodynamic therapy with pharmaceuticals that alter vascular microenvironment.
    Busch T
    Retina; 2009 Jun; 29(6 Suppl):S36-8. PubMed ID: 19553798
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Design and synthesis of novel DFG-out RAF/vascular endothelial growth factor receptor 2 (VEGFR2) inhibitors: 2. Synthesis and characterization of a novel imide-type prodrug for improving oral absorption.
    Okaniwa M; Imada T; Ohashi T; Miyazaki T; Arita T; Yabuki M; Sumita A; Tsutsumi S; Higashikawa K; Takagi T; Kawamoto T; Inui Y; Yoshida S; Ishikawa T
    Bioorg Med Chem; 2012 Aug; 20(15):4680-92. PubMed ID: 22763369
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Species differences in ocular pharmacokinetics and pharmacological activities of regorafenib and pazopanib eye-drops among rats, rabbits and monkeys.
    Horita S; Watanabe M; Katagiri M; Nakamura H; Haniuda H; Nakazato T; Kagawa Y
    Pharmacol Res Perspect; 2019 Dec; 7(6):e00545. PubMed ID: 31763044
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Photoreceptor status after antivascular endothelial growth factor therapy in exudative age-related macular degeneration.
    Sayanagi K; Sharma S; Kaiser PK
    Br J Ophthalmol; 2009 May; 93(5):622-6. PubMed ID: 19208677
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluation of injection frequency and visual acuity outcomes for ranibizumab monotherapy in exudative age-related macular degeneration.
    Dadgostar H; Ventura AA; Chung JY; Sharma S; Kaiser PK
    Ophthalmology; 2009 Sep; 116(9):1740-7. PubMed ID: 19643484
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Synthesis, Src kinase inhibitory and anticancer activities of 1-substituted 3-(N-alkyl-N-phenylamino)propane-2-ols.
    Sharma D; Sharma RK; Bhatia S; Tiwari R; Mandal D; Lehmann J; Parang K; Olsen CE; Parmar VS; Prasad AK
    Biochimie; 2010 Sep; 92(9):1164-72. PubMed ID: 20447438
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Retinal vascular permeability suppression by topical application of a novel VEGFR2/Src kinase inhibitor in mice and rabbits.
    Scheppke L; Aguilar E; Gariano RF; Jacobson R; Hood J; Doukas J; Cao J; Noronha G; Yee S; Weis S; Martin MB; Soll R; Cheresh DA; Friedlander M
    J Clin Invest; 2008 Jun; 118(6):2337-46. PubMed ID: 18483622
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluation of a series of naphthamides as potent, orally active vascular endothelial growth factor receptor-2 tyrosine kinase inhibitors.
    Weiss MM; Harmange JC; Polverino AJ; Bauer D; Berry L; Berry V; Borg G; Bready J; Chen D; Choquette D; Coxon A; DeMelfi T; Doerr N; Estrada J; Flynn J; Graceffa RF; Harriman SP; Kaufman S; La DS; Long A; Neervannan S; Patel VF; Potashman M; Regal K; Roveto PM; Schrag ML; Starnes C; Tasker A; Teffera Y; Whittington DA; Zanon R
    J Med Chem; 2008 Mar; 51(6):1668-80. PubMed ID: 18324759
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Natural history of predominantly classic, minimally classic, and occult subgroups in exudative age-related macular degeneration.
    Shah AR; Del Priore LV
    Ophthalmology; 2009 Oct; 116(10):1901-7. PubMed ID: 19592101
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Risk factors for second eye progression to advanced age-related macular degeneration: SST report No. 21 Submacular Surgery Trials Research Group.
    ; Solomon SD; Jefferys JL; Hawkins BS; Bressler NM; Bressler SB
    Retina; 2009 Sep; 29(8):1080-90. PubMed ID: 19734762
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Results of one-year's treatment with ranibizumab for exudative age-related macular degeneration in a clinical setting.
    Cohen SY; Dubois L; Tadayoni R; Fajnkuchen F; Nghiem-Buffet S; Delahaye-Mazza C; Guiberteau B; Quentel G
    Am J Ophthalmol; 2009 Sep; 148(3):409-13. PubMed ID: 19477713
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Anti-vascular endothelial growth factor therapy for neovascular ocular diseases other than age-related macular degeneration.
    Ciulla TA; Rosenfeld PJ
    Curr Opin Ophthalmol; 2009 May; 20(3):166-74. PubMed ID: 19381089
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Macular translocation - a therapeutic approach for neovascular macular degeneration in the era of anti-VEGF therapy?].
    Ziemssen F; Gelisken F
    Klin Monbl Augenheilkd; 2009 Jan; 226(1):31-7. PubMed ID: 19173161
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Structure-based virtual screening of Src kinase inhibitors.
    Lee K; Kim J; Jeong KW; Lee KW; Lee Y; Song JY; Kim MS; Lee GS; Kim Y
    Bioorg Med Chem; 2009 Apr; 17(8):3152-61. PubMed ID: 19321350
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Expression of vasohibin, an antiangiogenic factor, in human choroidal neovascular membranes.
    Wakusawa R; Abe T; Sato H; Yoshida M; Kunikata H; Sato Y; Nishida K
    Am J Ophthalmol; 2008 Aug; 146(2):235-243. PubMed ID: 18486097
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Novel 2,3-dihydro-1,4-benzoxazines as potent and orally bioavailable inhibitors of tumor-driven angiogenesis.
    La DS; Belzile J; Bready JV; Coxon A; DeMelfi T; Doerr N; Estrada J; Flynn JC; Flynn SR; Graceffa RF; Harriman SP; Larrow JF; Long AM; Martin MW; Morrison MJ; Patel VF; Roveto PM; Wang L; Weiss MM; Whittington DA; Teffera Y; Zhao Z; Polverino AJ; Harmange JC
    J Med Chem; 2008 Mar; 51(6):1695-705. PubMed ID: 18311900
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.